174 related articles for article (PubMed ID: 33444071)
1. Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial?
Agrawal AK; Michlitsch J; Golden C; Hastings CA; Raphael R; Feusner JH
J Clin Oncol; 2021 Feb; 39(6):694. PubMed ID: 33444071
[No Abstract] [Full Text] [Related]
2. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia.
Pandey RK; DiPippo A; Kadia T; Pemmaraju N; Workeneh BT; Jabbour E; Ravandi F; Jain N
Leuk Lymphoma; 2020 Nov; 61(11):2775-2777. PubMed ID: 32654562
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
4. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
[No Abstract] [Full Text] [Related]
5. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
[TBL] [Abstract][Full Text] [Related]
6. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
Miller LH; Maxa KL; Winter SS; Gossai NP
Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
[TBL] [Abstract][Full Text] [Related]
7. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
8. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
9. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
10. Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia.
Ghara N; Saha V
Lancet Haematol; 2023 Jun; 10(6):e391-e393. PubMed ID: 37167993
[No Abstract] [Full Text] [Related]
11. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
12. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
[TBL] [Abstract][Full Text] [Related]
13. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
[TBL] [Abstract][Full Text] [Related]
15. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
[TBL] [Abstract][Full Text] [Related]
17. Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.
Nishijima TF; Shea TC; Wood WA; Voorhees PM; Jamieson K
Leuk Lymphoma; 2016; 57(4):957-60. PubMed ID: 26293208
[No Abstract] [Full Text] [Related]
18. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
Hartz B; Löbel U; Hagel C; Escherich G
Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
[No Abstract] [Full Text] [Related]
19. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
[TBL] [Abstract][Full Text] [Related]
20. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]